NA
VIVO

Neuburgh Advisers’s Meridian Bioscience Inc VIVO Stock Holding History

Neuburgh Advisers’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-59,400
Closed -$1.05M – 894
2016
Q4 		$1.05M Buy
+59,400
New +$1.04M 0.05% 230

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Neuburgh Advisers's VIVO Position: Q1 2017 in Review

Neuburgh Advisers sold out of Meridian Bioscience Inc (VIVO) in Q1 2017, closing a stake of 59,400 shares — an estimated $1.05M sold.

Neuburgh Advisers first reported a position in VIVO in Q4 2016 and held it in 1 quarter. The position peaked at $1.05M in Q4 2016. 165 funds tracked by Wall St. Rank hold VIVO as of Q1 2017.

  • Neuburgh Advisers reported no remaining Meridian Bioscience Inc position as of Q1 2017 after selling out during the quarter.
  • Neuburgh Advisers sold 59,400 Meridian Bioscience Inc shares in Q1 2017, an estimated $1.05M.
  • Neuburgh Advisers first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 1 quarter.
  • Neuburgh Advisers's Meridian Bioscience Inc position peaked at $1.05M in Q4 2016.
  • 165 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2017.

Based on Neuburgh Advisers's 13F filing for Q1 2017, filed 5 May 2017.